Pristiq is owned by Pf Prism Cv.
Pristiq contains Desvenlafaxine Succinate.
Pristiq has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Pristiq are:
Pristiq was authorised for market use on 29 February, 2008.
Pristiq is available in tablet, extended release;oral dosage forms.
Pristiq can be used as for the approved uses and conditions of use, including depression; maintenance treatment of major depressive disorder (mdd).
The generics of Pristiq are possible to be released after 05 July, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US6673838||PF PRISM CV||Succinate salt of O-desmethyl-venlafaxine|| |
(10 months ago)
|US8269040||PF PRISM CV||Derivatives of venlafaxine and methods of preparing and using the same|| |
(4 years from now)
Market Authorisation Date: 29 February, 2008
Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)
Dosage: TABLET, EXTENDED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic